I expect the PPS to rally and Dr Reddy to rethink entering the market.
Why? What will be the Order? What will limit Dr. Reddy to enter?
- - - - - studythosestocks #327693
If they win the lawsuit then Hikma not any of the generics can sell their product outside of the high trigs >500 indication This means we lose only 10% or less of the US market
Hikma or any of the generics can sell their product for he high trigs >500 indication only already ... Do you expect the 10% lose only? Do you expect no generic will be dispensed outside of the high trigs >500 indication? ... Will not the direct infringement exist due to lack of inducement?
This increases scripts, lower tiers since there is no generic equivalent.
? No generic for R-IT indication ... Do you expect that gV will be dropped from Tier 1?
kiwi--you're 100% correct. Other generics will not try to compete even in the over 500 trig market b/b it is not worth the investment for an insubstantial profit/market.
The other generics will not enter b/c even if they are smarter than Hickma's management and don't make infringement statements--they cannot remove the cardio limitation (b/c that is induced infringement), and if they leave in the limitation then their product is not useable for cardiac benefit under 500 trigs.